On January 9, 2020, the board of directors of Xenon Pharmaceuticals Inc. (the “Company”) appointed Dr. Clarissa Desjardins as a director of the Company, effective as of January 13, 2020. In addition, on January 8, 2020, Dr. Richard Scheller, submitted his resignation from the Board, effective January 14, 2020. As a result of Dr. Scheller’s resignation and Dr. Desjardins’ appointment, Dr. Desjardins was appointed to the Board's Compensation Committee replacing Dr. Scheller effective as of January 13, 2020. Following Dr. Desjardins’ appointment to the Board's Compensation Committee, the membership on the three standing committees of the Board is as follows- Audit Committee: Frank Holler (Chair); Steven Gannon; and Michael Tarnow. Compensation Committee: Dr. Mohammad Azab (Chair); Dr. Clarissa Desjardins; and Dr. Gary Patou. Nominating and Corporate Governance Committee: Dr. Gary Patou (Chair); Dawn Svoronos; and Michael Tarnow.